174 related articles for article (PubMed ID: 27643535)
1. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
3. PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
Thanh Nha Uyen L; Amano Y; Al-Kzayer LFY; Kubota N; Kobayashi J; Nakazawa Y; Koike K; Sakashita K
Int J Hematol; 2020 Mar; 111(3):451-462. PubMed ID: 31865541
[TBL] [Abstract][Full Text] [Related]
4. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
5. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
6. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
8. PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer.
Yang Y; Liu J; Li X; Li JC
Histol Histopathol; 2012 Feb; 27(2):217-24. PubMed ID: 22207556
[TBL] [Abstract][Full Text] [Related]
9. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
Lin YL; Wang YP; Li HZ; Zhang X
Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
Lin YL; Li YL; Ma JG
Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
[TBL] [Abstract][Full Text] [Related]
12. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
[TBL] [Abstract][Full Text] [Related]
13. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
14. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
15. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation.
Byzia E; Soloch N; Bodnar M; Szaumkessel M; Kiwerska K; Kostrzewska-Poczekaj M; Jarmuz-Szymczak M; Szylberg L; Wierzbicka M; Bartochowska A; Kalinowicz E; Grenman R; Szyfter K; Marszalek A; Giefing M
Mol Carcinog; 2018 Jul; 57(7):878-885. PubMed ID: 29566279
[TBL] [Abstract][Full Text] [Related]
16. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.
Roman-Gomez J; Jimenez-Velasco A; Cordeu L; Vilas-Zornoza A; San Jose-Eneriz E; Garate L; Castillejo JA; Martin V; Prosper F; Heiniger A; Torres A; Agirre X
Eur J Cancer; 2007 Dec; 43(18):2736-46. PubMed ID: 18032022
[TBL] [Abstract][Full Text] [Related]
17. ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia.
Abdullah M; Choo CW; Alias H; Abdul Rahman EJ; Mohd Ibrahim H; Jamal R; Hussin NH
Hematology; 2017 Aug; 22(7):386-391. PubMed ID: 28292214
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
[TBL] [Abstract][Full Text] [Related]
19. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.
Baranova I; Kovarikova H; Laco J; Dvorak O; Sedlakova I; Palicka V; Chmelarova M
Cancer Biomark; 2018; 23(1):125-133. PubMed ID: 29991130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
